The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis

BACKGROUND: Irinotecan (IRI)-based and oxaliplatin (OXA)-based regimens are available for the treatment of metastatic colorectal cancer (mCRC). Several studies have published inconsistent results in their comparisons of the efficacy and toxicity of IRI ± bevacizumab and OXA ± bevacizumab. This meta-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Medicine (Baltimore)
Autori principali: Dai, Jiali, Chen, Yuetong, Gong, Yang, Wei, Jingsun, Cui, Xiaowen, Yu, Hualin, Zhao, Wenjing, Gu, Dongying, Chen, Jinfei
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wolters Kluwer Health 2019
Soggetti:
5700
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6775432/
https://ncbi.nlm.nih.gov/pubmed/31574891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000017384
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi